Back to Search
Start Over
Role of CD39 in COVID-19 Severity: Dysregulation of Purinergic Signaling and Thromboinflammation.
- Source :
-
Frontiers in immunology [Front Immunol] 2022 Jan 31; Vol. 13, pp. 847894. Date of Electronic Publication: 2022 Jan 31 (Print Publication: 2022). - Publication Year :
- 2022
-
Abstract
- CD39/NTPDase1 has emerged as an important molecule that contributes to maintain inflammatory and coagulatory homeostasis. Various studies have hypothesized the possible role of CD39 in COVID-19 pathophysiology since no confirmatory data shed light in this regard. Therefore, we aimed to quantify CD39 expression on COVID-19 patients exploring its association with severity clinical parameters and ICU admission, while unraveling the role of purinergic signaling on thromboinflammation in COVID-19 patients. We selected a prospective cohort of patients hospitalized due to severe COVID-19 pneumonia (n=75), a historical cohort of Influenza A pneumonia patients (n=18) and sex/age-matched healthy controls (n=30). CD39 was overexpressed in COVID-19 patients' plasma and immune cell subsets and related to hypoxemia. Plasma soluble form of CD39 (sCD39) was related to length of hospital stay and independently associated with intensive care unit admission (adjusted odds ratio 1.04, 95%CI 1.0-1.08, p=0.038), with a net reclassification index of 0.229 (0.118-0.287; p=0.036). COVID-19 patients showed extracellular accumulation of adenosine nucleotides (ATP and ADP), resulting in systemic inflammation and pro-coagulant state, as a consequence of purinergic pathway dysregulation. Interestingly, we found that COVID-19 plasma caused platelet activation, which was successfully blocked by the P2Y <subscript>12</subscript> receptor inhibitor, ticagrelor. Therefore, sCD39 is suggested as a promising biomarker for COVID-19 severity. As a conclusion, our study indicates that CD39 overexpression in COVID-19 patients could be indicating purinergic signaling dysregulation, which might be at the basis of COVID-19 thromboinflammation disorder.<br />Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.<br /> (Copyright © 2022 Díaz-García, García-Tovar, Alfaro, Zamarrón, Mangas, Galera, Ruíz-Hernández, Solé-Violán, Rodríguez-Gallego, Van-Den-Rym, Pérez-de-Diego, Nanwani-Nanwani, López-Collazo, García-Rio and Cubillos-Zapata.)
- Subjects :
- Adenosine Diphosphate analysis
Adenosine Triphosphate analysis
Biomarkers blood
Blood Platelets immunology
Cell Hypoxia physiology
Critical Care statistics & numerical data
Female
Humans
Influenza A virus immunology
Influenza, Human pathology
Length of Stay
Male
Middle Aged
Platelet Activation immunology
Prognosis
Prospective Studies
Purinergic P2Y Receptor Antagonists pharmacology
SARS-CoV-2 immunology
Severity of Illness Index
Signal Transduction immunology
Thromboinflammation immunology
Ticagrelor pharmacology
Apyrase blood
Apyrase metabolism
COVID-19 pathology
Receptors, Purinergic P2Y metabolism
Thromboinflammation pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1664-3224
- Volume :
- 13
- Database :
- MEDLINE
- Journal :
- Frontiers in immunology
- Publication Type :
- Academic Journal
- Accession number :
- 35173744
- Full Text :
- https://doi.org/10.3389/fimmu.2022.847894